A vaccine against the biggest bacterial killer on the planet is a step closer to being available with funding secured for preclinical trials.
Professor James Paton, Director of the University of Adelaide’s Research Centre for Infectious Diseases and his team have been working on a vaccine for Streptococcus pneumoniae (the pneumococcus) that could save two million lives globally a year and address the overuse of antibiotics that leads to resistance.
“The pneumococcus is the biggest bacterial killer on the planet. It’s the most common cause of pneumonia, which is responsible for about 20 per cent of deaths from all causes in children under 5 years in developing countries. Globally, the pneumococcus accounts for about two million deaths a year,” says Professor Paton.
Streptococcus pneumoniae, which is principally spread through close contact with infected but asymptomatic carriers, is the leading cause of sinus and ear infections, meningitis, sepsis and pneumonia. Ear infections are one of the most common childhood illnesses that are habitually treated with antibiotics, contributing to increasing bacterial resistance.
“Vaccinating people against Streptococcus pneumoniae would help to ameliorate the global challenge of increasing bacterial resistance to antibiotics,” says Professor Paton.
“The problem with the existing pneumococcal vaccine is that it targets the outside coat of complex carbohydrates – of which there are 98 structurally distinct types. The current vaccine costs about $150 a dose and only covers 13 types.
“What we have done is to remove this coat to expose all the surface proteins that are common to all pneumococcal types. The body mounts an immune response to these surface proteins if previously exposed or vaccinated.”
Sixteen months ago, Adelaide-based GPN Vaccines Pty Ltd was created to develop this novel “whole bacterial” vaccine (Gamma-PNTM) against Streptococcus pneumoniae. The company has already secured investment from local angel investors as well as a major grant from the National Health & Medical Research Council and a Commercialisation grant from the South Australian Government.
GPN Vaccines has now raised a further AUS$1.1 million from international and Australian-based investors that will be used for preclinical evaluation of the Gamma-PNTM vaccine. Toxicity tests will be carried out as well as the scale-up clinical grade manufacture of the vaccine in readiness for testing in a first-in-human clinical trial.
Learn more: STEP FORWARD FOR PNEUMONIA VACCINE DEVELOPMENT
The Latest on: Pneumonia
via Google News
The Latest on: Pneumonia
- ASK AYNE: Don't overdo pneumonia vaccine or Halloween candyon October 26, 2019 at 8:14 pm
Q: I want to make sure I keep up to date with the pneumonia vaccine. I had the pneumonia vaccine a few years ago but I am not sure if you are supposed to get it every year like the flu vaccine. A: The ...
- Radiomics Nomogram Analyses for Differentiating Pneumonia and Acute Paraquat Lung Injuryon October 25, 2019 at 10:27 am
We sought to develop and validate a radiomics nomogram incorporating radiomics signature and laboratory bio-markers, for differentiating bacterial pneumonia and acute paraquat lung injury. 180 ...
- Flu shots benefit patients hospitalized with pneumoniaon October 24, 2019 at 6:05 am
Routine, in-hospital influenza vaccinations for all adults hospitalized with pneumonia may save lives and reduce hospitalizations, according to a study presented at CHEST 2019, the annual meeting of ...
- Philips' New CSR Campaign to Knock-Down Childhood Pneumonia in Indiaon October 23, 2019 at 6:20 am
The health technology company Royal Philips' subsidiary Philips India, launches a CSR campaign 'HarSaansMeinZindagi'. This campaign is launched to spread awareness about childhood pneumonia in India.
- ‘Days of Our Lives’ star John Clarke dead at 88 following bout of pneumoniaon October 22, 2019 at 8:59 am
Soap opera star John “Jack” Clarke has died at 88. A representative for Clarke, who spent 39 years playing Mickey Horton on NBC’s “Days of Our Lives,” confirmed to Deadline Monday that the actor had ...
- 'Days of Our Lives' alum John Clarke dies at 88 from 'complications of pneumonia': reportson October 22, 2019 at 5:32 am
Actor John Clarke, who embodied Mickey Horton on "Days of Our Lives" for decades has died, according to reports. He died on Oct. 16 as a result of "complications of pneumonia," per Entertainment ...
- Risk for Death From Pneumonia Rises Without Flu Vaccineon October 21, 2019 at 1:46 pm
When a patient with pneumonia is admitted to the hospital, a flu shot can reduce the risk for readmission and death, report investigators. Pneumonia accounts for 50% of deaths during the flu season, ...
- Routine flu vaccination for adults hospitalized with pneumonia can reduce readmissions, mortalityon October 21, 2019 at 10:56 am
NEW ORLEANS — In-hospital influenza vaccination may reduce 30-day readmissions, mortality, morbidity and health care resource utilization in adults with community-acquired pneumonia. In a study ...
- Pneumonia Vaccine Market Size, Future Forecast, Key Manufactures And Competitors Analysis, 2025 | GlaxoSmithKline, Pfizer, Merckon October 18, 2019 at 3:08 am
Oct 18, 2019 (Reporthive Research via COMTEX) -- Chicago, United States, Oct 18, 2019 -- Report Hive has recently published a research report, titled Pneumonia Vaccine Market. The report aims to open ...
- New Pneumonia Guidance: Testing, Treating, and Follow-upon October 15, 2019 at 1:06 pm
An updated clinical guideline on pneumonia emphasizes antimicrobial stewardship with recommendations for increased microscopic studies of respiratory tract specimens in certain patients and revised ...
via Bing News